Oxybutynin

Articles · Medicine Compliance Aid Stability · Lactation Safety Information ·

35768004

Articles

Drugs for urinary disorders – are any lactose-free?

This Medicine Q&A gives details of available urinary frequency, enuresis, incontinence and urinary retention preparations that do not contain lactose. There is a lactose-free preparation… Alfuzosin Bethanechol Darifenacin Desmopressin Doxazosin Duloxetine Dutasteride Finasteride Imipramine Lactose Mirabegron Oxybutynin Prazosin Propiverine Q&A Renal and urologic disorders Solifenacin Solifenacin + Tamsulosin Tamsulosin Tamsulosin + Dutasteride Tolterodine Trospium

Drug-induced hypersalivation – what treatment options are available?

This Medicines Q&A summarises published studies or case reports concerning the pharmacological treatment of drug-induced hypersalivation (drooling or sialorrhoea), particularly hypersalivation caused by clozapine.   Amisulpride Atropine Benzatropine Biperiden Botulinum A toxin Bupropion Clonidine Clozapine Glycopyrronium Guanfacine Hyoscine butylbromide Hyoscine hydrobromide Ipratropium Lofexidine Metoclopramide Moclobemide Oxybutynin Pirenzepine Propantheline Q&A Quetiapine Sulpiride Trihexyphenidyl

Medicine Compliance Aid Stability

Ditropan · Sanofi-Aventis

Sanofi-Aventis
Ditropan
Tablets 2.5mg, 5mg
R2 · Red 2 · Drug is not suitable for CAs due to theoretical reasons that cannot be mitigated.
Unsuitable
Protect from light
29th September 2015

Lyrinel XL · Janssen-Cilag Ltd

Janssen-Cilag Ltd
Lyrinel XL
Tablets m/r 5mg, 10mg
R2 · Red 2 · Drug is not suitable for CAs due to theoretical reasons that cannot be mitigated.
Unsuitable
Hygroscopic. Stored with a dessicant.
21st September 2015

Cystrin · Zentiva

Zentiva
Cystrin
Tablets 2.5mg, 3mg, 5mg
A3 · Amber 3 · No stability data is available. There are theoretical concerns with use in CAs, which may be mitigated by risk minimisation.
Airtight container
Protect from light
Store in airtight, light resistant container.
1st October 2015

Lactation Safety Information

Low levels anticipated in milk due to the drug's properties
No published evidence of safety
Monitor infant for anticholinergic effects, e.g. urinary retention, colic and constipation